Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.5K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.5K
Nonsense-mediated mRNA Decay02:27

Nonsense-mediated mRNA Decay

11.6K
The Upf proteins that carry out nonsense-mediated decay (NMD) are found in all eukaryotic organisms, including humans. Each protein has an individual role, but they need to work in collaboration. Upf1 is an ATP-dependent RNA helicase that unwinds the RNA helix. Because Upf1 can unwind any RNA, Upf2 and Upf3 are required to help Upf1 discriminate between nonsense and normal mRNAs.
Usually, Upf3 binds to an Exon Junction Complex (EJC) at mRNA splice sites. If a ribosome fully translates the mRNA,...
11.6K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

715
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
715

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of genetic variants in the longevity gene PPARGC1A and cerebrospinal fluid PPARγ levels on clinical trajectories in Parkinson's disease: Potential biomarkers for neurodegeneration and ageing.

Parkinsonism & related disorders·2026
Same author

Staphylococcal proliferation on skin models to investigate novel anti-infective treatments against dysbiosis.

Bioengineering & translational medicine·2026
Same author

Inter-assay and Inter-site Performance of Alpha-Synuclein Seed Amplification Assays in Synucleinopathies: A Multicenter 2 × 2 Protocol Comparison.

Neurology and therapy·2026
Same author

HERA: a web server for host element reference-based aligner.

Nucleic acids research·2026
Same author

Spatio-temporal gait signatures across prodromal and early Parkinson's disease in two independent cohorts.

Scientific reports·2026
Same author

RegRegSEA: a web server for regulatory region set enrichment analysis of epigenomic data.

Nucleic acids research·2026

Related Experiment Video

Updated: Jan 2, 2026

Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
09:47

Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches

Published on: December 15, 2023

1.6K

Machine Learning to Detect Alzheimer's Disease from Circulating Non-coding RNAs.

Nicole Ludwig1, Tobias Fehlmann2, Fabian Kern2

  • 1Department of Human Genetics, Saarland University, 66421 Homburg/Saar, Germany.

Genomics, Proteomics & Bioinformatics
|December 7, 2019
PubMed
Summary

Blood-borne microRNAs (miRNAs) show promise for Alzheimer's disease (AD) diagnostics. This study validated 21 circulating miRNAs, finding 20 consistently altered in AD patients, with potential for a blood-based diagnostic test.

Keywords:
Alzheimer’s diseaseBiomarkerGene regulationNeurodegenerationNon-coding RNAsmiRNAs

More Related Videos

Identification of Circular RNAs using RNA Sequencing
08:25

Identification of Circular RNAs using RNA Sequencing

Published on: November 14, 2019

12.6K
Author Spotlight: Exploring Sex-Specific Glial Signatures and Therapeutic Leads for Alzheimer's Disease
04:22

Author Spotlight: Exploring Sex-Specific Glial Signatures and Therapeutic Leads for Alzheimer's Disease

Published on: May 20, 2024

1.2K

Related Experiment Videos

Last Updated: Jan 2, 2026

Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
09:47

Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches

Published on: December 15, 2023

1.6K
Identification of Circular RNAs using RNA Sequencing
08:25

Identification of Circular RNAs using RNA Sequencing

Published on: November 14, 2019

12.6K
Author Spotlight: Exploring Sex-Specific Glial Signatures and Therapeutic Leads for Alzheimer's Disease
04:22

Author Spotlight: Exploring Sex-Specific Glial Signatures and Therapeutic Leads for Alzheimer's Disease

Published on: May 20, 2024

1.2K

Area of Science:

  • Biomarkers and Diagnostics
  • Neuroscience
  • Molecular Biology

Background:

  • Small non-coding RNAs (sncRNAs) in blood are promising candidates for non-invasive diagnostic tests.
  • Previous high-throughput sequencing identified microRNA (miRNA) signatures in Alzheimer's disease (AD).
  • Validation in larger cohorts and statistical evaluation are crucial for biomarker development.

Purpose of the Study:

  • To validate and quantify the expression levels of 21 known circulating miRNAs in a large cohort of AD patients and controls.
  • To assess the correlation between miRNA expression levels and AD phenotypes, gender, age, and disease severity (Mini-Mental State Examination; MMSE).
  • To evaluate the diagnostic potential of these miRNAs for AD using machine learning models.

Main Methods:

  • Quantitative reverse transcription PCR (RT-qPCR) was used to determine the abundance levels of 21 circulating miRNAs in 465 individuals.
  • Statistical models were computed to analyze the relationship between miRNA expression and clinical parameters.
  • Machine learning algorithms were employed to assess the diagnostic accuracy of miRNA signatures in differentiating AD patients from controls.

Main Results:

  • Expression levels of 20 out of 21 miRNAs were consistently dysregulated in both US and German AD cohorts.
  • Eighteen miRNAs significantly correlated with neurodegeneration, with miR-532-5p showing the highest significance (adjusted P = 4.8 × 10-30).
  • Machine learning models achieved an Area Under the Curve (AUC) of 87.6% for AD diagnosis. Ten miRNAs correlated with MMSE scores, notably miR-26a/26b-5p.

Conclusions:

  • Circulating miRNAs, particularly miR-532-5p and miR-26a/26b-5p, are robust biomarkers for Alzheimer's disease diagnosis and severity.
  • The study provides strong evidence for the translational potential of a miRNA-based blood test for AD.
  • Differential enrichment of miRNAs in specific immune cell types (monocytes, T-helper, B-cells) and serum exosomes suggests underlying biological mechanisms in AD pathogenesis.